the proportion remaining free from new T2 lesions detected by MRI. 26 A disadvantage with IFNβ therapy in some patients is the development of neutralising antibodies and this is associated with reduced efficacy, [27] [28] [29] [30] [31] [32] particularly in patients with persistently high titres of antibodies. Such patients often benefit from switching to a non-IFNβ therapy. 33 For patients who relapse despite using IFNβs or glatiramer acetate, the next treatment options are natalizumab or mitoxantrone. Both natalizumab and mitoxantrone can be highly effective in treating refractory cases of relapsing MS, but mitoxantrone is decreasingly used. 14, 15, 34, 35 However, both of these drugs are associated with serious adverse events (AE) and therefore are generally used as second-line options, although use as first-line therapy may be warranted in selected cases. 14, 15, 36, 37 Evaluation of pooled clinical trial data has shown that, compared with placebo, approximately 0.1% of patients treated with natalizumab for 18 months developed the rare but potentially
Alemtuzumab -A New Efficacy Benchmark in Relapsing-Remitting Multiple Sclerosis? 40 Furthermore, the risk of developing mitoxantrone-therapy-related acute leukaemia was 0.74% in one retrospective study, 41 which is much higher than the rate observed in clinical studies. 40 With the exception of the recently approved oral medication, fingolimod, the other approved DMDs for use in MS require regular administration (daily, every other day, weekly or monthly [in the case of natalizumab]) by injection for indefinite periods to allow optimal outcomes. 42 Injection anxiety and injection-site reactions can discourage patients resulting in low adherence, particularly during the first few months of treatment, leading to suboptimal health outcomes. [42] [43] [44] In addition, some patients may have difficulty following the correct dosing regimen or injection technique. 43 Finally, a lack of perceived efficacy is the main reason for discontinuation of therapy despite the fact that some therapies require longer courses to show health benefits. 
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Mode of Action of Alemtuzumab
Alemtuzumab is a humanised mAb that targets CD52, a glycoprotein on the surface of various blood cell types (T-and B-lymphocytes, monocytes and eosinophils). 55 CD52 antigens are expressed at high density on T-and B-lymphocytes but at lower density on cells of the innate immune system and not on haematological precursor cells. 53, 56 Once bound to CD52, alemtuzumab triggers antibody-mediated cytotoxicity and complement fixation; 57 subsequent lymphocyte depletion and cytokine induction appear to be mediated by neutrophils and natural killer cells. 58 However, the exact mode of action of alemtuzumab and the exact function of CD52 are not fully understood.
The distribution of CD52 may account for the selective and beneficial mode of action of alemtuzumab and for the transient depletion of
Multiple Sclerosis Pre-clinical mechanism of action studies on alemtuzumab have been limited by a lack of cross-reactivity between human and mouse CD52.
However, significant insights into alemtuzumab's mechanism of action have been gained via studies in the recently developed transgenic mouse that expresses human CD52 (hCD52) under control of the hCD52 promoter. 58 The tissue distribution of hCD52 and immune function in the transgenic mice were normal. Treating the mice with alemtuzumab transiently increased serum cytokines and reduced blood lymphocytes in a manner that was similar to the response seen in humans. However, lymphocyte depletion was not as marked in lymphoid organs including the spleen, thymus and lymph nodes; this could explain why patients receiving alemtuzumab show a lower incidence of infection than might be anticipated. In mice, eliminating populations of natural killer cells and neutrophils with antibodies to Gr-1 or asialo-GM-1, respectively, markedly reduced the effects of alemtuzumab but removal of complement using cobra venom factor had no effect. These findings indicate that lymphocyte depletion resulting from alemtuzumab therapy relies primarily on antibody-dependent cell-mediated cytotoxicity as opposed to complement-dependent cytotoxicity. An overview of these potential mechanisms of action is shown in Table 2 .
After alemtuzumab treatment, immune reconstitution follows a unique characteristic pattern in which B cells return towards baseline levels within three months while T cells take up to five years to recover. 59,60 Following peripheral lymphocyte depletion, it has been postulated that naïve myelin-specific T cells could be tolerised, preventing their neurodegenerative activity. 56 This property could provide alemtuzumab with immunomodulatory properties in addition to depleting lymphocytes. 59 Furthermore, in vitro analysis has shown that alemtuzumab may increase the lymphocytic delivery of neurotrophins to the central nervous system promoting survival of neurons and increased axonal length. 54 This potential neurorestorative action may partly explain the observed improvement in disability after alemtuzumab administration, although much work is required to further elucidate this effect. Overall, it appears that the benefits of alemtuzumab therapy in MS rest not on lymphocyte depletion per se, but rather in a long-term shift in the lymphocyte repertoire.
Alemtuzumab Clinical Trial Data
Initial pilot studies ( Alemtuzumab -A New Efficacy Benchmark in Relapsing-Remitting Multiple Sclerosis? Figure 2) .
The four-year follow-up of CAMMS223 patients show that the efficacy advantages of alemtuzumab compared with IFNβ-1a were sustained over long-term durations despite the fact that no further doses of alemtuzumab were given after two years and that the majority had not received a dose for three years. 63 In the pooled alemtuzumab Three-year data for the CAMMS223 trial show that the overall proportion of patients receiving alemtuzumab who reported AEs was greater than the proportion receiving IFNβ-1a. In the alemtuzumab groups, the most common AEs reported were infusion-associated reactions (98.6%). These reactions were confined to the alemtuzumab group due to the method of administration. These reactions included rash (91.7%), headache (61.1%), pyrexia (37.5%), fatigue (27.8%), pruritus (25.0%) and nausea (24.1%).
Notable AEs occurring in both the alemtuzumab (pooled analysis) and IFNβ-1a groups were: autoimmune thyroid disorders (23 and 3%), idiopathic thrombocytopenic purpura (ITP) (3 and 1%) and infections (66 and 47%). 62 Among the other events, the most frequent were influenza-like illness (4 versus 27%; p<0.001), fatigue (31 versus 30%), headache (31 versus 28%), pyrexia (11 versus 10%) and rash (26 versus 14%). Apart from influenza-like symptoms, the differences in incidence in these events between alemtuzumab-and IFNβ-1a-treated groups were not significant.
62
The first case of ITP went unrecognised and following several weeks of typical symptoms, presented with a fatal cerebral haemorrhage.
However, the other ITP cases were self-limiting or responsive to treatment, all patients achieved durable remission and no ITP was reported >16 months after treatment. 65 It was previously hypothesised that patients who had autoimmune AEs following alemtuzumab had a fundamentally different immune reconstitution and may be less likely to respond to treatment compared with patients without such events.
The study data show that this is not the case; patients with autoimmune events through 36 months showed a 66% reduction in the risk of SAD (p=0.03) and a 78% reduction in risk of relapse
Multiple Sclerosis 
No change Improvement
Proportion of patients showing decline, no change or improvement in disability scores during treatment with interferon beta-1a (IFNβ-1a) (44μg continuously, subcutaneous injection) or alemtuzumab (12 or 24mg per day intravenous infusion*) in the CAMMS223 trial (three-year data). *Alemtuzumab dosing regimen is for five days initially, then for three days
Kaplan-Meier analysis of sustained accumulation of disability in patients treated with interferon beta-1a (IFNβ-1a) subcutaneous (SC) or alemtuzumab (alem.) (pooled 12 or 24mg dose groups) during the Campath-1H in Multiple Sclerosis (CAMMS223) trial and follow-up. Source: Coles et al., 2010. 61
patients who experienced autoimmunity were equally likely to benefit from alemtuzumab efficacy as those without such events.
In the CAMMS223 trial, one patient developed antiglomerular basement membrane (anti-GBM, Goodpastures syndrome). The patient developed hypothyroidism at month 24 (day 733) and at month 51 (39 month after the second alemtuzumab cycle), showed increased serum creatinine (1.9mg/dl at diagnosis and peaking at 2.8mg/dl) with haematuria. A renal biopsy showed anti-GBM. The patient also had an upper respiratory infection and rash, which are typical of anti-GBM, just prior to the onset of haematuria. The patient was treated with a course of plasmapheresis, cyclophosphamide and steroids. Seventeen months after diagnosis, the patient remains in remission with elevated but stable serum creatinine and is MS relapse-free. In CAMMS223 to date, only one patient has developed anti-GBM disease (frequency 0.5%, event rate one per 981 patient-years).
63,67
In MS patient populations treated with alemtuzumab to date, the incidence of any serious opportunistic infections has been low; and the infections that have occurred were mostly of mild to moderate severity. 62,65 However, the immunosuppressive effects of alemtuzumab may be selective with relative sparing of the lymphoid organs including the spleen, thymus and lymph nodes. These observations demonstrate a favourable safety profile but larger phase III trial safety data are awaited.
Hypotheses Concerning Delayed or Secondary Autoimmunity
The mechanism of action of alemtuzumab and the process by which it might induce secondary autoimmunity in a subset of MS patients have received attention in several studies. Recent clinical data on a subset of 94 of the 232 patients in the CAMMS223 trial who had RRMS and received alemtuzumab, has shown that those who develop lymphopenia-associated autoimmunity (mainly to the thyroid gland)
have greater levels of T-cell apoptosis and T-cell cycling driven by substantially higher baseline levels (two-fold) of interleukin 21 (IL-21) than patients who do not develop autoimmunity. 68 The study also showed that IL-21 expression is genetically pre-determined. It was proposed that following lymphocyte depletion by alemtuzumab, overproduction of IL-21 in some individuals results in excess T-cell cycling and apoptosis and thereby increases the stochastic opportunities for T-cells to encounter self antigen, break tolerance and for autoimmunity to develop. Increased IL-21 levels may also act to promote B-cell differentiation and antibody production. 56 Therefore, IL-21 levels could be used as a biomarker prior to alemtuzumab treatment, to indicate which patients may be at increased risk of developing secondary autoimmunity.
Other immunological studies have shown that although lymphocytes are repeatedly depleted during cycles of alemtuzumab treatment, the capacity of the immune system to regenerate remains unimpaired.
After exposure to alemtuzumab, B-cell reconstitution is rapid with levels returning to baseline by three months and to higher levels by 12 months. 60 The most abundant B cell subtype one month after Alemtuzumab -A New Efficacy Benchmark in Relapsing-Remitting Multiple Sclerosis? 
Study design of (A) Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I study (CARE-MS I) and (B) Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II study (CARE-MS II). *Exploratory 24mg intravenous (IV) group with limited recruitment. IFNβ = interferon beta; SC = subcutaneous.
19. Polman CH, O'Connor PW, Havrdova E, et al., A randomized, placebo-controlled trial of natalizumab for (see Figure 4) . The end-points are similar to CARE-MS I. Together, the IFNβ-1a-treated patients will receive annual courses of alemtuzumab (12mg per day for five days initially then for three days after 12 months) and then will have the option of further treatment based on the same criteria for the patients previously treated with alemtuzumab. The extension study is designed to assess the long-term efficacy and safety of alemtuzumab, define criteria for additional as needed alemtuzumab therapy and determine the safety and effectiveness of the alemtuzumab in patients who switch from
IFNβ. As with the phase III studies, the extension study will include risk-monitoring programmes for autoimmune disease.
Implications of Study Data
The efficacy data from the phase II CAMMS223 trial provide strong evidence that alemtuzumab represents a major advance in the treatment of RRMS. Improvements over IFNβ-1a were seen in terms of reducing relapse rates, reducing both the number of lesions, the 
Future Developments
In the future, there will be a greater choice of DMDs available to the neurologist for MS treatment. Choosing either of the current injectable agents, new oral agents or existing and new monoclonal antibody therapies will require an understanding of the therapeutic role of these medications and the development of guidelines.
Immunomodulators have made great progress in the last few years, but it will be important for patients to be carefully monitored to ensure ongoing therapeutic effect. A patient must have a decreased number of relapses and reduced relapse severity compared with the pre-therapeutic phase, slowed disease progression and a lack of severe side effects that reduce QoL. The order in which MS treatments are used and methods for optimal dosing in individual patients will also need to be defined. As more clinical data become available, escalating immunotherapy options will need to be redefined. 33, 73 The role of biomarkers in therapeutic monitoring and clinical outcomes is also likely to emerge in the near future, providing further guidance to the clinician. 
